Netherlands· NL-d5a820ea261d
Ethosuximide Strides 250 mg zachte capsules
A ethosuximide product containing ethosuximide, registered in Netherlands by Strides Pharma (Cyprus) Limited. The same ATC class is registered in 16 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Ethosuximide is registered in 16 of 19 countries.
Countries holding a registration under ATC N03AD01 (ethosuximide), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Ethosuximide · ATC N03AD01
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ethosuximide costs, country by country.
Normalised to the WHO defined daily dose (1.25 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ethosuximide · price per daily dose (1.25 g)
USD · FX 28 Sept 2026
- CH Switzerland$1.83
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- ETHOSUXIMIDE
- Manufacturer
- Strides Pharma (Cyprus) Limited
- Country
- Netherlands (NL)
- ATC code
- N03AD01
- ATC class
- Ethosuximide
- Defined daily dose
- 1.25 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id123574
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
124 interactions on record for ethosuximide.
Graded by severity as the source publishes them — 124 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ethosuximide · interactions on record
124 records
- 124 moderate
Most severe, free to view
- MetoclopramideA03FA01moderate
- ThiethylperazinA04AB03moderate
- DiphenhydraminA04AB05moderate
- DronabinolA04AD10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ethosuximide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomEmeside 250mg capsulesFontus Health Ltd
- United StatesEthosuximideEpic Pharma, LLC
- CanadaMAR-ETHOSUXIMIDEMARCAN PHARMACEUTICALS INC
- SwitzerlandPetinimid, Weichkapselnaxapharm ag
- SpainETOSUXIMIDA FAES 250 mg CAPSULAS DURASFaes Farma S.A.
- PolandPetinimidG.L. Pharma GmbH
- SwedenEthosuximide 2care4 250 mg Kapsel, mjuk2care4 ApS
- GermanyEthosuximid GlenmarkGlenmark Arzneimittel Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 18 EEA countries. Names it is sold under:
- Austria · Ethosuximid Neuraxpharm, Petinimid
- Belgium · Zarontin
- Bulgaria · Petinimid
- Czechia · Petinimid
- Germany · Ethosuximid Glenmark, Ethosuximid Neuraxpharm
- Denmark · Ethosuximide Orifarm, Ethosuximide Strides
- Spain · Etosuximida Faes
- France · Zarontin
- United Kingdom (Northern Ireland) · Emeside, Epesri
- Croatia · Suxital
- Ireland · Zarontin
- Italy · Etosuccimide Glenmark, Zarontin
- Luxembourg · Zarontin
- Norway · Ethosuximide Orifarm, Ethosuximide Strides
- Poland · Petinimid
- Sweden · Ethosuximide Orifarm, Ethosuximide Strides
- Slovenia · Suxital
- Slovakia · Petinimid Cps, Petnidan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9e23b47f-161d-4166-87f8-c6a25eaf5b31 GET /v1/drugs/9e23b47f-161d-4166-87f8-c6a25eaf5b31?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, zacht",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h123574_smpc.pdf",
"strength": null,
"atc_label": "Ethosuximide",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg123574",
"excipients": [
"ERYTHROSINE (E 127)",
"GELATINE (E 441)",
"GLYCEROL (E 422)",
"MACROGOL 400",
"SORBITOL, VLOEIBAAR, NIET-KRISTALLISEERBAAR (E 420)",
"WATER, GEZUIVERD"
],
"substances": [
"ETHOSUXIMIDE"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h123574.pdf",
"authorised_at": "2019/08/21",
"procedure_number": "NL/H/4514/001",
"dispensing_status": "Uitsluitend recept",
"registration_number": "123574",
"additional_monitoring": "N"
}See everything about ethosuximide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.